A CLOSER LOOK GBL/COR/0916/1075 U.S

Size: px

Start display at page:

Download "A CLOSER LOOK GBL/COR/0916/1075 U.S"

Lee Francis
5 years ago
Views:

1 A CLOSER LOOK

2 AbbVie: An Introduction We re a biopharmaceutical company. We re guided by people, powered by passion, and in awe of the possibilities ahead of us. We re highly focused, research oriented, and patient centric. We are AbbVie. 2

3 Mission Our mission is to build a world class, innovation driven, patient focused, specialty biopharmaceutical company. Capable of delivering top tier performance through outstanding execution and a consistent stream of new medicines. 3

4 History 125 YEARS of patient care Launched as AbbVie in ,000 + dedicated employees Millions of lives touched 4

5 Impact on Science 5

6 Investing in Science At AbbVie, we have the commitment, expertise, and capabilities to provide life changing products to patients who need them most 6,670+ SCIENTISTS 1 IN 10 ABBVIE EMPLOYEES CARRY A DOCTORATE 6

year 50+ ACTIVE CLINICAL DEVELOPMENT PROGRAMS 122,000 PATIENTS

7 Investing in Science There are numerous programs in mid and latestage development that continue to help fill our robust pipeline year over year 50+ ACTIVE CLINICAL DEVELOPMENT PROGRAMS 122,000 PATIENTS PARTICIPATED IN CLINICAL TRIALS GLOBALLY IN ,000+ PATIENTS IN THE U.S. IN

INVENTORS CONTRIBUTED TO 100+ PATENTS IN 2015 WE RE DISCOVERING

8 Investing in Science ~ $3.6 BILLION * INTO RESEARCH AND DEVELOPMENT IN 2015 ~ 500 ABBVIE INVENTORS CONTRIBUTED TO 100+ PATENTS IN 2015 WE RE DISCOVERING AND TESTING COMPOUNDS THAT COULD POTENTIALLY TREAT 482 MILLION PATIENTS * NON GAAP, ADJUSTED R&D SPEND 8

9 Partnerships & Collaboration Our broad network: Through collaboration, we advance science and innovation, the lifeblood of our company. Recent acquisitions include Pharmacyclics and Stemcentrx PARTNERS INCLUDE APPROXIMATELY 270 LEADING BIOTECHS, UNIVERSITIES, NONPROFITS, AND GOVERNMENT ORGANIZATIONS 9

$Therapeutic Areas of Focus Oncology We currently have treatment approved in relapsed/refractory Chronic Lymphocytic Leukemia with 17p deletion, Mantle Cell Lymphoma and Waldenstrom s$

10 Therapeutic Areas of Focus Oncology We currently have treatment approved in relapsed/refractory Chronic Lymphocytic Leukemia with 17p deletion, Mantle Cell Lymphoma and Waldenstrom s Macroglobulinemia. Future areas of focus include: Leveraging our experience in immunology to develop next generation immuno oncology therapies Growing a strong position in hematologic malignancies Establishing a foundation in solid tumors 10

gastroenterology ABBVIE MEDICINE TREATS + 1 MILLION PATIENTS IN 14 INDICATIONS WORLDWIDE

11 Therapeutic Areas of Focus Immunology We have been leveraging deep scientific expertise to develop next generation biologics and small molecules in rheumatology, dermatology and gastroenterology ABBVIE MEDICINE TREATS + 1 MILLION PATIENTS IN 14 INDICATIONS WORLDWIDE 20 NEW MOLECULES TESTING IN 14 DISEASE STATES 196 IMMUNOLOGY STUDIES IN MORE THAT 50 COUNTRIES 11

Therapeutic Areas of Focus Virology AbbVie s Hepatitis C virus (HCV) clinical development program is intended to advance scientific knowledge and the clinical care of people with chronic HCV

12 Therapeutic Areas of Focus Virology AbbVie s Hepatitis C virus (HCV) clinical development program is intended to advance scientific knowledge and the clinical care of people with chronic HCV infection Neuroscience We re developing innovative therapies for neurological degenerative disorders, such as Parkinson s disease, multiple sclerosis (MS), and Alzheimer s disease AbbVie established the Foundational Neuroscience Center in Cambridge in

13 Targeted Investment At AbbVie, we re applying our significant resources toward break throughs in areas that touch many, at all life stages. Focused investments in areas that fit our core strengths include: Endometriosis Uterine fibroids Cystic fibrosis collaborations Diabetic kidney disease 13

14 Impact on Economies 14

15 Jobs and the Economy Globally, AbbVie creates jobs and stimulates local economies. 28,000+ EMPLOYEES GLOBALLY 13,000+ EMPLOYEES IN THE U.S. 15

16 Impact Worldwide 8 State of the Art Research and Development Facilities 16

17 Impact Worldwide 13 Manufacturing Centers 17

18 We create global impact, through our people by their passion, reveling in possibilities. 18

19 PEOPLE. PASSION. POSSIBILITIES. ABBVIE.COM ABBVIEFOUNDATION.COM A CLOSERLOOK

J.P. Morgan Healthcare Conference

J.P. Morgan Healthcare Conference Michael Severino Vice Chairman and President January 9, 2019 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation are, or